Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.39 |
| ▸ | TEC | P42680 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24714585 | 1.00 | EGFR (0.43) | EGFRERBB2SRCRIPK2RET | |
| SCHEMBL24714494 | 0.92 | EGFR (0.43) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL30031590 | 0.92 | EGFR (0.43) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL24714473 | 0.90 | EGFR (0.39) | EGFRERBB2SRC | |
| SCHEMBL30031238 | 0.88 | EGFR (0.56) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL24713982 | 0.88 | EGFR (0.56) | EGFRERBB2RIPK2RETMET | |
| SCHEMBL30031577 | 0.86 | EGFR (0.41) | EGFRERBB2SRC | |
| SCHEMBL24714602 | 0.86 | EGFR (0.41) | EGFRERBB2SRC | |
| SCHEMBL26129597 | 0.77 | ERBB2 (0.64) | EGFRERBB2 | |
| SCHEMBL24715219 | 0.76 | EGFR (0.50) | EGFRERBB2RIPK2RETMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | disclosed |
| WO-2022225238-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 보로노이 주식회사 | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885SRC 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.